Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Is Weekend-Only Physical Activity Enough to Compensate for a Sedentary Lifestyle?

Is Weekend-Only Physical Activity Enough to Compensate for a Sedentary Lifestyle? Letters measuring changes in health-related quality of life, symp- pedited because of their importance to patients. In the toms, or function “…have suffered from methodological is- meantime, cancer drugs without survival or QOL benefit must sues and poor data quality, limiting their use in regulatory de- undergo rapid withdrawal as outlined in the Federal Food, 4 5 cisions.” They indicate that those methodological weaknesses Drug, and Cosmetic Act and the Code of Federal Regulations, justify keeping drugs on the market when there is no clear evi- although this process unfortunately remains rare and slow to dence of clinical benefit. However, there are numerous reli- occur. able, validated quality-of-life measures that are used in We find the claim of Blumenthal and colleagues that it is research ; they have been and should be used to determine not practical to require drug companies to conduct phase III whether oncology drugs have a significant impact, or they trials capable of detecting changes in overall survival among should be revised to be more appropriate to measure such im- patients with chronic myeloid leukemia or multiple myeloma pact. Blumenthal and colleagues give several examples where to be contradicted by their following statements that “…thera- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Is Weekend-Only Physical Activity Enough to Compensate for a Sedentary Lifestyle?

Loading next page...
 
/lp/american-medical-association/is-weekend-only-physical-activity-enough-to-compensate-for-a-sedentary-UEAk3Jz0pL
Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2017.2380
Publisher site
See Article on Publisher Site

Abstract

Letters measuring changes in health-related quality of life, symp- pedited because of their importance to patients. In the toms, or function “…have suffered from methodological is- meantime, cancer drugs without survival or QOL benefit must sues and poor data quality, limiting their use in regulatory de- undergo rapid withdrawal as outlined in the Federal Food, 4 5 cisions.” They indicate that those methodological weaknesses Drug, and Cosmetic Act and the Code of Federal Regulations, justify keeping drugs on the market when there is no clear evi- although this process unfortunately remains rare and slow to dence of clinical benefit. However, there are numerous reli- occur. able, validated quality-of-life measures that are used in We find the claim of Blumenthal and colleagues that it is research ; they have been and should be used to determine not practical to require drug companies to conduct phase III whether oncology drugs have a significant impact, or they trials capable of detecting changes in overall survival among should be revised to be more appropriate to measure such im- patients with chronic myeloid leukemia or multiple myeloma pact. Blumenthal and colleagues give several examples where to be contradicted by their following statements that “…thera-

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Aug 1, 2017

References